XML 124 R100.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions and Divestitures - Narrative (Details)
$ / shares in Units, shares in Millions, SFr in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 22, 2022
USD ($)
$ / shares
Oct. 01, 2020
USD ($)
Apr. 04, 2021
USD ($)
Jan. 01, 2023
USD ($)
Jan. 02, 2022
USD ($)
shares
Jan. 02, 2022
CHF (SFr)
shares
Jan. 03, 2021
USD ($)
$ / shares
shares
Jan. 03, 2021
CHF (SFr)
shares
Jan. 03, 2021
CHF (SFr)
Business Acquisition [Line Items]                  
Consideration transferred         $ 7,300        
Liabilities assumed         400        
Goodwill (Notes 1 and 5)       $ 45,231 35,246   $ 36,393    
Long-term debt       28,439 32,116        
Asset write-downs       1,216 989   233    
Payments to Acquire Businesses, Gross       17,700          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities       1,100          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets       17,300          
Finite-Lived Intangible Asset, Useful Life 14 years                
Contingent consideration liability       1,120 533        
Deferred tax liability, acquisition       1,800          
Goodwill, related to acquisitions       11,056 0        
In-process research and development       783 900   $ 181    
Acquisition related costs       300          
Non-Tradeable Contingent Value Right                  
Business Acquisition [Line Items]                  
Dividends Payable, Amount Per Share | $ / shares $ 8.75                
Non-Tradeable Contingent Value Right | Class I Recommendation For Impella                  
Business Acquisition [Line Items]                  
Dividends Payable, Amount Per Share | $ / shares $ 10.00                
Idorsia                  
Business Acquisition [Line Items]                  
Sale of stock, number of shares issued in transaction (in shares) | shares             11.8 11.8  
Sale of stock, percentage of ownership before transaction             8.30% 8.30%  
Proceeds from sale of equity interests             $ 357 SFr 337.0  
Sale of stock (in USD per share) | $ / shares             $ 28.55    
Convertible note, equity Interest (in shares) | shares             38.7 38.7  
Momenta                  
Business Acquisition [Line Items]                  
Consideration transferred   $ 6,100              
Liabilities assumed   $ 1,600              
Discount rate   13.00%              
Goodwill (Notes 1 and 5)   $ 1,200              
Other assets assumed   500              
Momenta | In Process Research and Development                  
Business Acquisition [Line Items]                  
Intangible assets assumed   $ 6,000              
2020 Acquisitions | In Process Research and Development                  
Business Acquisition [Line Items]                  
Purchase price over fair value of assets acquired         7,500        
bermekimab                  
Business Acquisition [Line Items]                  
Consideration transferred     $ 800            
Intangible assets assumed     $ 800            
Discount rate     16.00%            
Asset write-downs       800          
Verb Surgical Inc.                  
Business Acquisition [Line Items]                  
Liabilities assumed     $ 300            
Intangible assets assumed     400            
Goodwill (Notes 1 and 5)     200            
Other assets assumed     200            
Equity method investments, fair value     $ 400            
Abiomed                  
Business Acquisition [Line Items]                  
Discount rate 9.50%                
Other assets assumed $ 19,900                
Marketable securities assumed 600                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities $ 2,800                
Acquisition price (in dollars per share) | $ / shares $ 380.00                
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable $ 17,100                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents 16,500                
Contingent consideration liability 700     $ 704          
Deferred tax liability, acquisition 1,800                
Cash Acquired from Acquisition 300                
Goodwill, related to acquisitions 10,900                
Finite-lived Intangible Assets Acquired 6,600                
In-process research and development 1,100                
Abiomed | Non-Tradeable Contingent Value Right                  
Business Acquisition [Line Items]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right $ 1,600                
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right | $ / shares $ 35.00                
Dividends Payable, Amount Per Share | $ / shares $ 17.50                
Revenues, Contingent Consideration $ 3,700                
Abiomed | Non-Tradeable Contingent Value Right | Impella                  
Business Acquisition [Line Items]                  
Dividends Payable, Amount Per Share | $ / shares $ 7.50                
Maximum | Momenta                  
Business Acquisition [Line Items]                  
Probability of success factor   77.00%              
Maximum | bermekimab                  
Business Acquisition [Line Items]                  
Probability of success factor     60.00%            
Maximum | Abiomed                  
Business Acquisition [Line Items]                  
Probability of success factor 70.00%                
Minimum | Momenta                  
Business Acquisition [Line Items]                  
Probability of success factor   20.00%              
Minimum | bermekimab                  
Business Acquisition [Line Items]                  
Probability of success factor     20.00%            
Minimum | Abiomed                  
Business Acquisition [Line Items]                  
Probability of success factor 52.00%                
Convertible Debt | Idorsia                  
Business Acquisition [Line Items]                  
Long-term debt | SFr                 SFr 445.0
Convertible debt, amount of loan converted         $ 120 SFr 110.0      
Convertible Debt, number of equity instruments (in shares) | shares         9.6 9.6      
Evra and Doxil                  
Business Acquisition [Line Items]                  
Proceeds from divestiture of brands         $ 600